The whole drug industry has been under pressure for the past 30 years and is having more and more trouble coming up with new drugs. R&D costs are increasing so he doesn't like the pharmaceutical industry in general. In response to a question regarding the currency component he doesn't feel it is an issue.
It has outperformed the sector. The technicals are OK but but it is not in a great space. He owns some but would not buy more at this time.
Eli Lilly & Co. is a American stock, trading under the symbol LLY-N on the New York Stock Exchange (LLY). It is usually referred to as NYSE:LLY or LLY-N
In the last year, 13 stock analysts published opinions about LLY-N. 12 analysts recommended to BUY the stock. 1 analyst recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Eli Lilly & Co..
Eli Lilly & Co. was recommended as a Top Pick by on . Read the latest stock experts ratings for Eli Lilly & Co..
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
13 stock analysts on Stockchase covered Eli Lilly & Co. In the last year. It is a trending stock that is worth watching.
On 2023-03-22, Eli Lilly & Co. (LLY-N) stock closed at a price of $330.97.
Has done well. Their diabetes drug is effective for weight loss, which is pending approval, but would open a new market. She expects approval. Stock price reflects this approval though. Weight loss is a lucrative market given obesity levels around the world. The PE is too high for her, but may buy on a pullback.